Please select the option that best describes you:
Topics:
Radiation Oncology • Neuro-Oncology • Medical Oncology • Brain Metastases • Neurology • ASTRO 2025
How will you select patients with brain metastases for TTFields?
The METIS study included only NSCLC patients and found a greater impact for patients previously treated with ICI. How does this impact your patient selection?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Plenary Session Presentation "Tumor Treating Fields (TTFields) After Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM): Final Results of The Phase 3 METIS Trial" by Dr. Vinai Gondi.
Answer from: Radiation Oncologist at Academic Institution
The METIS trial restricted eligibility only to patients with brain metastases from non-small cell lung cancer. Therefore, we would not be able to extrapolate these results and data to other tumor types and histologies. Indeed, a post hoc analysis of the data did demonstrate a greater impact in patie...
Sign in or Register to read more